REGISTER
MedJ at ESMO 2025 with Dr. Solange Peters
Interest in MedJ at ESMO 2025 with Dr. Solange Peters is rising as new results accumulate. It distills the central data on ESMO, MD, DAREON-8 into a clear account of the article's most important conclusions.

Solange Peters, MD, Lausanne University Hospital, Switzerland

On-site Interpretation of the DAREON-8 Study – The Bispecific Antibody Obrixtamig Combined with Standard Therapy Brings New Momentum to First-Line Treatment for Slowly Progressing Extensive-Stage Small Cell Lung Cancer After Immunochemotherapy!

0
0
Loading